Related Experiment Video

Updated: May 25, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

MMPs in ovarian cancer as therapeutic targets

Amer Karam1, Oliver Dorigo

  • 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

Anti-Cancer Agents in Medicinal Chemistry
|February 2, 2012
PubMed

Insights

Matrix metalloproteinases (MMPs) are key drivers of ovarian cancer metastasis. Targeting these enzymes offers a promising strategy to improve survival rates for patients with advanced ovarian cancer.

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Ovarian cancer has a poor 5-year survival rate (30%) for advanced stages.
  • Current treatments (surgery, chemotherapy) have limitations.
  • Matrix metalloproteinases (MMPs) are implicated in ovarian cancer progression and metastasis.

Purpose of the Study:

  • To review the expression and biological role of MMPs in ovarian cancer.
  • To summarize clinical trial data on targeting MMPs for ovarian cancer treatment.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of MMP expression patterns in ovarian tumors.
  • Evaluation of therapeutic strategies targeting MMPs.

Main Results:

  • MMPs are frequently expressed in ovarian cancer.
  • MMPs play a critical role in tumor cell invasion and metastasis.
  • Clinical trials targeting MMPs show potential but require further investigation.

Conclusions:

  • MMPs represent a viable therapeutic target for ovarian cancer.
  • Targeting MMPs may improve survival and cure rates.
  • Further research is needed to optimize MMP-targeted therapies.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...